Overlapping network meta-analyses on psoriasis systemic treatments, an overview: quantity does not make quality
- PMID: 34854074
- DOI: 10.1111/bjd.20908
Overlapping network meta-analyses on psoriasis systemic treatments, an overview: quantity does not make quality
Abstract
Background: Network meta-analyses (NMAs) have become successful in addressing gaps in the comparative effectiveness of systemic treatments in moderate-to-severe psoriasis. However, their increasing number carries both a risk of overlap and reproducibility issues that can hamper clinical decision-making.
Objectives: In this overview, we aimed to assess redundancy across these NMAs and to describe their characteristics.
Materials and methods: We considered all systematic reviews with NMAs of randomized controlled trials that included adult patients with moderate-to-severe psoriasis and that evaluated the efficacy and/or safety of systemic treatments compared with placebo or with an active comparator. PubMed/MEDLINE, Epistemonikos, PROSPERO and the Evidence update of the Centre of Evidence-Based Dermatology of the University of Nottingham were searched up to 25 February 2021. Our main outcome was the number per year of redundant NMAs and the extent of their overlap. We also described their features, especially, the confidence in the results of the reviews, the funding of the studies and the presence of spin (a description that overstates efficacy and/or understates harm), reporting issues and methodological characteristics.
Results: In total, 47 redundant NMAs were included. Only two of 47 (4%) included all available treatments. Both efficacy and safety were evaluated in 14 of 47 (30%) NMAs and both short- and long-term evaluations were assessed in five of 47 (11%). Confidence in the results was critically low for 39 of 47 (83%) NMAs and only 10 of 47 (21·3%) registered a protocol. Twenty-six of 47 NMAs (55%) received pharmaceutical funding. Contract research organizations were involved in 19 of 47 (40%) NMAs. Reporting was poor across most of the NMA abstracts and spin was present in all of the abstracts. Almost half of the NMAs failed to consider important limitations such as heterogeneity (considered in 32%) or consistency (considered in 66%).
Conclusions: In addition to a duplication of efforts, our overview showed heterogeneous methods and poor confidence in the results in a majority of the included NMAs, further distorted by reporting issues and spin. Clinicians need to interpret NMAs with caution when looking for the most reliable and comprehensive evidence.
© 2022 British Association of Dermatologists.
Comment in
-
'Quantity does not make quality': when is there a case for repeating a network meta-analysis?Br J Dermatol. 2022 May;186(5):911-913. doi: 10.1111/bjd.21017. Epub 2022 Mar 16. Br J Dermatol. 2022. PMID: 35080030 No abstract available.
-
Response to 'Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours'.Br J Dermatol. 2022 May;186(5):913-914. doi: 10.1111/bjd.20970. Epub 2022 Mar 24. Br J Dermatol. 2022. PMID: 35322414 No abstract available.
-
Systemic treatments for psoriasis: not another network meta-analysis!Br J Dermatol. 2022 Jul;187(1):3-4. doi: 10.1111/bjd.21601. Epub 2022 May 3. Br J Dermatol. 2022. PMID: 35506185 Free PMC article.
References
-
- Boehncke W-H, Schön MP. Psoriasis. Lancet 2015; 386:983-94.
-
- Parisi R, Iskandar IYK, Kontopantelis E et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369:m1590.
-
- Afach S, Evrenoglou T, Oubaya N et al. Most randomized controlled trials for psoriasis used placebo comparators despite the availability of effective treatments. J Clin Epidemiol 2021; 133:72-9.
-
- Chaimani A, Caldwell DM, Li T et al. Chapter 11: Undertaking network meta-analyses. In: Cochrane Training Handbook. Available at: https://training.cochrane.org/handbook/current/chapter-11 [accessed 27 November 2021].
-
- Ioannidis JPA. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q 2016; 94:485-514.

